Show simple item record

dc.contributor.authorLittle, Marken
dc.date.accessioned2021-02-23T10:03:10Z
dc.date.available2021-02-23T10:03:10Z
dc.date.issued2020en
dc.date.submitted2020en
dc.identifier.citationMoiseev, S., Cohen Tervaert, J.W., Arimura, Y., Bogdanos, D.P., Csernok, E., Damoiseaux, J., Ferrante, M., Flores-Su?rez, L.F., Fritzler, M.J., Invernizzi, P., Jayne, D., Jennette, J.C., Little, M.A., McAdoo, S.P., Novikov, P., Pusey, C.D., Radice, A., Salama, A.D., Savige, J.A., Segelmark, M., Shoenfeld, Y., Sinico, R.A., Sousa, M.-J., Specks, U., Terrier, B., Tzioufas, A.G., Vermeire, S., Zhao, M.-H., Bossuyt, X., 2020 international consensus on ANCA testing beyond systemic vasculitis, Autoimmunity Reviews, 19, 9, 2020en
dc.identifier.otherYen
dc.identifier.urihttp://hdl.handle.net/2262/95297
dc.descriptionPUBLISHEDen
dc.description.abstractThis document follows up on a 2017 revised international consensus on anti-neutrophil cytoplasm antibodies (ANCA) testing in granulomatosis with polyangiitis and microscopic polyangiitis and focuses on the clinical and diagnostic value of ANCA detection in patients with connective tissue diseases, idiopathic interstitial pneumonia, autoimmune liver diseases, inflammatory bowel diseases, anti-glomerular basement membrane (GBM) disease, infections, malignancy, and during drug treatment. Current evidence suggests that in certain settings beyond systemic vasculitis, ANCA may have clinical, pathogenic and/or diagnostic relevance. Antigen-specific ANCA targeting proteinase-3 and myeloperoxidase should be tested by solid phase immunoassays in any patient with clinical features suggesting ANCA-associated vasculitis and in all patients with anti-GBM disease, idiopathic interstitial pneumonia, and infective endocarditis associated with nephritis, whereas in patients with other aforementioned disorders routine ANCA testing is not recommended. Among patients with autoimmune liver diseases or inflammatory bowel diseases, ANCA testing may be justified in patients with suspected autoimmune hepatitis type 1 who do not have conventional autoantibodies or in case of diagnostic uncertainty to discriminate ulcerative colitis from Crohn’s disease. In these cases, ANCA should be tested by indirect immunofluorescence as the target antigens are not yet well characterized. Many questions concerning the optimal use of ANCA testing in patients without ANCA-associated vasculitis remain to be answered.en
dc.language.isoenen
dc.relation.ispartofseriesAutoimmunity Reviewsen
dc.relation.ispartofseries19en
dc.relation.ispartofseries9en
dc.rightsYen
dc.title2020 international consensus on ANCA testing beyond systemic vasculitisen
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/mlittleen
dc.identifier.rssinternalid224247en
dc.identifier.doihttps://doi.org/10.1016/j.autrev.2020.102618en
dc.rights.ecaccessrightsopenAccess
dc.subject.TCDThemeImmunology, Inflammation & Infectionen
dc.identifier.rssurihttps://doi.org/10.1016/j.autrev.2020.102618en
dc.identifier.orcid_id0000-0001-6003-397Xen


Files in this item

This item appears in the following Collection(s)

Show simple item record